Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Ecallantide

Abstract

In December 2009, ecallantide (Kalbitor; Dyax) — a recombinant protein inhibitor of plasma kallikrein — was approved by the US FDA for the treatment of acute attacks of hereditary angioedema.

Your institute does not have access to this article

Relevant articles

Open Access articles citing this article.

Access options

Buy article

Get time limited or full article access on ReadCube.

$32.00

All prices are NET prices.

Figure 1: Pathogenesis of hereditary angioedema and therapeutic interventions.

References

  1. Davis, A. E. 3rd. New treatments addressing the pathophysiology of hereditary angioedema. Clin. Mol. Allergy 6, 2 (2008).

    Article  Google Scholar 

  2. Schneider, L. et al. Critical role of kallikrein in hereditary angioedema pathogenesis: a clinical trial of ecallantide, a novel kallikrein inhibitor. J. Allergy Clin. Immunol. 120, 416–422 (2007).

    CAS  Article  Google Scholar 

  3. Bork, K., Yasothan, U & Kirkpatrick, P. Icatibant. Nature Rev. Drug Discov. 7, 801–802 (2008).

    CAS  Article  Google Scholar 

  4. Nussberger, J. et al. Plasma bradykinin in angio-oedema. Lancet 351, 1693–1697 (1998).

    CAS  Article  Google Scholar 

  5. US Food and Drug Administration. FDA labelling information — Kalbitor (ecallantide). FDA website [online], (2009).

  6. Ley, A. C. et al. Obtaining a family of high-affinity, high-specificity protein inhibitors of plasmin and plasma kallikrein. Mol. Divers. 2, 119–124 (1996).

    CAS  Article  Google Scholar 

  7. Markland, W. et al. Iterative optimization of high-affinity protease inhibitors using phage display. 2. Plasma kallikrein and thrombin. Biochemistry 35, 8058–8067 (1996).

    CAS  Article  Google Scholar 

  8. IMS MIDAS (IMS Health, 2009).

  9. Nadeau, P. et al. SG Cowen Biotechnology Report (6 Jan 2010).

    Google Scholar 

  10. Monane, M. et al. Needham Investment Analysis (2 Dec 2009).

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Ethics declarations

Competing interests

B.Z. has participated in research with Lev Pharmaceuticals and Pharming AG, and has been a paid consultant for Dyax Inc., Jerini, Shire, CSL Behring and ViroPharma.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Zuraw, B., Yasothan, U. & Kirkpatrick, P. Ecallantide. Nat Rev Drug Discov 9, 189–190 (2010). https://doi.org/10.1038/nrd3125

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrd3125

Further reading

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing